Hydrogenation process for the formation of tetrahydro HMG-CoA reductase inhibitors
US4864035A · kind A · utility
0Cited by
3References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 1987 |
| Grant date | Sep 5, 1989 |
| Priority date | — |
| Expiry date | Sep 3, 2007 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F7/1804
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A novel hydrogenation process, using a homogenous iridium or rhodium catalyst for the reduction of both double bonds of des-(.alpha.-methylbutyryl)-C-8-hydroxy lovastatin and C-8-amino, C-8-alkoxy and C-6-substituted analogs, is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.